Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Paul Lieberman
Wistar Institute, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Vironika, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The NIH-funded research closely parallels the research being conducted by the company, namely the development of chemical compounds for treatment of Epstein-Barr Virus Latent Infection and associated diseases. Dr. Lieberman’s equity ownership in an entity whose financial interest could be affected by the design, conduct, or reporting of work pursuant to his NIH-funded research constitutes a potential financial conflict of interest.
Regulation of EBV Latency by EBNA1
Epstein-�Barr virus (EBV) is estimated to be responsible for ~1% of all human cancer world-�wide, including most forms of post-�transplant lymphoproliferative disease, ~50% of Hodgkin?s disease, ~10% of gastric carcinomas, and the majority of endemic forms of Burkitt?s lymphoma and nasopharyngeal carcinomas. The overwhelming majority of EBV-�associated tumors harbor latent viral genomes that are maintained through the action of the viral encoded protein EBNA1. This grant focuses on the mechanisms of EBNA1-�mediated genome maintenance and how this contributes to both viral and host cell survival during latent infection. Increased understanding of EBNA1 function during latency is essential for development of therapeutic strategies for the treatment of EBV-�associated cancers and related disease
Filed on September 27, 2018.
Tell us what you know about Paul Lieberman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.